Global infectious disease drug development partnership aims to ‘stimulate pharma’

By Maggie Lynch contact

- Last updated on GMT

Global infectious disease drug development partnership aims to ‘stimulate pharma’

Related tags: Site selection, Pediatrics, Drug development, global market

Penta and Cromsource partner in an aim to improve pediatric drug development for infectious disease therapies worldwide.

The international contract research organization (CRO) Cromsource will work with the recently established Penta ID Innovation through this agreement. Penta ID Innovation is a site management organization developed from the Penta Global Pediatric Research Network.

Per the collaboration, Penta and Cromsource will work to establish and manage worldwide drug development programs for infectious diseases affecting pediatric populations.

Penta will bring its experience in pediatric infectious diseases to the table alongside Cromsource’s capabilities in managing global drug development programs for pediatric patients.

A spokesperson for Comsource and Penta told us that the partnership will target most pediatric infectious diseases and will “hopefully it will stimulate pharma to be more active in the field.”

According to the two companies, pediatric drug development poses several challenges that have to be taken into consideration. This includes patient enrollment and site selection, challenges which the companies aim to take on by involving many specialized sites in multiple countries.

 

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars